Clinical Effect Analysis of Frozen-Thawed-Deglycerolized Red Blood Cells
Acta Haematologica · 19.05.2026 · 1-8
DOI: 10.1159/000552369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 19.05.2026. Verfasst von Yajie Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Introduction
The aim of this study was to analyze the clinical infusion effect of frozen-thawed-deglycerolized red blood cells (FTD-RBCs) and provide solutions for situations such as blood supply shortages.
Methods
In this retrospective study, 280 patients receiving FTD-RBCs and 280 patients receiving suspended red blood cells (SRBCs) in our hospital from December 2019 to June 2022 were included. We collected the course records and laboratory test results, including basic information, total amount of transfusion, as well as RBC count, hemoglobin concentration (HGB), and hematocrit (HCT) 24 h before and after the transfusion, and whether there were adverse blood transfusion reactions. Clinical efficacy analysis of FTD-RBCs was conducted by Mann-Whitney U test and Kruskal-Wallis H test.
Results
In the 280 patients of our study, RBC count, HGB, and HCT increased significantly after transfusion of FTD-RBCs (p < 0.05). For transfusion of one FTD-RBC unit, the median differences in RBC count, HGB, and HCT before and after transfusion were 0.310 × 1012/L, 9.735 g/L, and 2.800%, respectively. The increments of the three indicators in the FTD-RBC group were all lower than those in the SRBC group, but the differences were not statistically significant (p > 0.05). None of the patients in this study had adverse transfusion reactions after transfusion of FTD-RBCs. In addition, we found that the efficacy of FTD-RBCs transfusion was associated with sex, age, body weight, disease type, and blood type of the patient (p < 0.05).
Conclusion
The infusion of FTD-RBCs for clinical patients is safe and effective, and it is an effective blood supply supplement in situations of blood shortage such as public health events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing, China, lixiaofei@ccmu.edu.cn.
Zitieren
APA
Wang, Y., Rao, Q., Ma, Y., Zhang, Y., & Li, X. (2026). Clinical Effect Analysis of Frozen-Thawed-Deglycerolized Red Blood Cells. Acta Haematologica, 1-8. https://doi.org/10.1159/000552369
Vancouver
Wang Y, Rao Q, Ma Y, Zhang Y, Li X. Clinical Effect Analysis of Frozen-Thawed-Deglycerolized Red Blood Cells. Acta Haematologica. 2026:1-8. doi:10.1159/000552369
BibTeX
@article{Wang2026,
author = {Wang, Yajie and Rao, Quan and Ma, Yiming and Zhang, Yuan and Li, Xiaofei},
title = {Clinical Effect Analysis of Frozen-Thawed-Deglycerolized Red Blood Cells},
journal = {Acta Haematologica},
year = {2026},
pages = {1--8},
doi = {10.1159/000552369}
}
EUVIMED